Home/Pipeline/Plamotamab (XmAb®13676)

Plamotamab (XmAb®13676)

B-cell Malignancies

Phase 2Active (Partnered)

Key Facts

Indication

B-cell Malignancies

Phase

Phase 2

Status

Active (Partnered)

Company

Xencor

About Xencor

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

View full company profile

Therapeutic Areas

Oncology Autoimmune Disorders Infectious Disease

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
BAFFR Allo CAR-NK Cells	PeproMene Bio	Pre-clinical	Active
IKS03	Iksuda Therapeutics	Clinical	Active
TNB-486	Ancora Bio	Phase 1	Active
docirbrutinib (AS-1763)	Carna Biosciences	Phase 1b	Active
Abivertinib	Sorrento Therapeutics	Phase 1/2	Active
Kymriah® (tisagenlecleucel)	Novartis	Approved	Active
KITE-363	Gilead Sciences	Phase 1/2	Active
HSK29116	Haisco Pharmaceutical Group	Phase I/II	Active
TG-1701	TG Therapeutics	Phase 1	Active
TG-1801	TG Therapeutics	Phase 1	Active
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
CAB-CD19 x CD3 T-cell Engager	BioAtla	Preclinical	IND-enabling